Scarica l'app Stockscreener
176.69
0.09%
-0.16
Precedente Chiudi:
$176.85
Aprire:
$176.72
Volume 24 ore:
885.34K
Relative Volume:
1.03
Capitalizzazione di mercato:
$10.42B
Reddito:
$551.35M
Utile/perdita netta:
$-189.33M
Rapporto P/E:
-53.68
EPS:
-3.2916
Flusso di cassa netto:
$-35.09M
1 W Prestazione:
+6.70%
1M Prestazione:
+10.53%
6M Prestazione:
+45.24%
1 anno Prestazione:
+130.58%
Intervallo 1D:
$174.21
$178.22
Intervallo di 1 settimana:
$164.09
$178.22
Portata 52W:
$73.16
$191.62
Glaukos Corp Stock (GKOS) Company Profile
Nome
Glaukos Corp
Settore
Industria
Telefono
949-367-9600
Indirizzo
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS vs ABT, MDT, SYK, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corp
|
176.69 | 10.42B | 551.35M | -189.33M | -35.09M | -3.2916 |
ABT
Abbott Laboratories
|
102.51 | 177.38B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
96.59 | 123.55B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
307.08 | 117.79B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
46.01 | 66.68B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.09 | 51.93B | 6.30B | 1.07B | 1.09B | 1.8406 |
Glaukos Corp Stock (GKOS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-07-28 | Iniziato | UBS | Neutral |
| 2026-07-06 | Iniziato | H.C. Wainwright | Buy |
| 2025-10-27 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-10-01 | Iniziato | Goldman | Buy |
| 2025-05-01 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-02-19 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2024-12-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-12-06 | Iniziato | UBS | Buy |
| 2024-12-02 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2024-07-10 | Downgrade | Citigroup | Buy → Neutral |
| 2024-05-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-12-21 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-12-04 | Iniziato | Morgan Stanley | Equal-Weight |
| 2023-11-28 | Iniziato | Truist | Buy |
| 2023-11-08 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-06-07 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-12-22 | Iniziato | Mizuho | Neutral |
| 2022-12-19 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-12-12 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-10-14 | Ripresa | Stephens | Overweight |
| 2022-10-04 | Iniziato | Needham | Buy |
| 2022-07-12 | Aggiornamento | Stifel | Hold → Buy |
| 2022-02-03 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2022-01-19 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2022-01-18 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2021-11-03 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2021-07-26 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2021-07-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2021-07-14 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-07-14 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-04-08 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-01-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Aggiornamento | Citigroup | Sell → Neutral |
| 2020-12-09 | Iniziato | Oppenheimer | Perform |
| 2020-11-17 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2020-10-08 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-06-15 | Iniziato | Jefferies | Hold |
| 2020-03-05 | Iniziato | Citigroup | Sell |
| 2020-02-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-01-06 | Aggiornamento | Berenberg | Hold → Buy |
| 2019-12-12 | Downgrade | Wells Fargo | Outperform → Underperform |
| 2019-09-30 | Downgrade | BofA/Merrill | Buy → Underperform |
| 2019-03-08 | Iniziato | BTIG Research | Neutral |
| 2018-08-30 | Iniziato | Berenberg | Hold |
| 2018-08-29 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-08-03 | Reiterato | Stifel | Hold |
| 2018-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-04-13 | Downgrade | Stifel | Buy → Hold |
| 2018-03-01 | Reiterato | Cantor Fitzgerald | Buy |
| 2017-03-02 | Reiterato | Cantor Fitzgerald | Overweight |
| 2017-01-06 | Aggiornamento | Stifel | Hold → Buy |
| 2016-10-27 | Iniziato | Wells Fargo | Outperform |
Mostra tutto
Glaukos Corp Borsa (GKOS) Ultime notizie
Price-Driven Insight from (GKOS) for Rule-Based Strategy - Stock Traders Daily
Glaukos Corporation (GKOS) Stock Forecasts - Yahoo Finance
Is Glaukos Corp (GKOS) Overvalued After 3.9% Rally? GF Value Say - GuruFocus
BTIG raises target for Glaukos stock to USD 205 - AD HOC NEWS
Glaukos Expands Retinal Pipeline With RevOpsis Deal - Orange County Business Journal
Forge’s Fierce Life Sciences Announces 2026 Fierce Innovation Awards Finalists and Unveils the Fierce Vanguard Gala - GlobeNewswire Inc.
Glaukos (NYSE:GKOS): High Growth Momentum Meets a Breakout Setup - ChartMill
Stifel reiterates Glaukos stock rating on strong iDose growth - Investing.com
Glaukos Corporation (GKOS) Reiterated at Buy by Stifel After Solid Q3 iDose Volume Diligence - StreetInsider
Mizuho lifts target for Glaukos stock to USD 190.00 - ad-hoc-news.de
Glaukos reports positive topline phase 4 data on iDose TR in combo with cataract surgery - Glance by Eyes On Eyecare
Glaukos Corporation (GKOS) Stock Forecasts - Yahoo! Finance Canada
Glaukos Corporation (GKOS) Stock forecasts - Yahoo Finance UK
Glaukos Corporation (GKOS) Stock Forecasts - Yahoo Finance
Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally? - Zacks Investment Research
Midday Stock Roundup: loanDepot Shares Continue Falling - Orange County Business Journal
Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally? - Zacks Investment Research
Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally? - TradingView
Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally? - Yahoo Finance
Glaukos reports positive 3-year, phase 3 Epioxa clinical outcomes - Glance by Eyes On Eyecare
Enrollment Complete in Glaukos Study of the PRESERFLO MicroShunt - Medical Product Outsourcing
Midday Stock Roundup: Karman Slips - Orange County Business Journal
GKOS Maintained by BTIG -- Price Target Raised to $205 - GuruFocus
(GKOS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Glaukos: Steep Premium For New Therapies And Growth (NYSE:GKOS) - Seeking Alpha
Glaukos Corporation (GKOS) Stock Forecasts - Yahoo! Finance Canada
Glaukos: The Second J-Code Rewrites The Risk Math - Seeking Alpha
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal - The Globe and Mail
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal - Barchart.com
Glaukos Corp (GKOS) Reports Positive Phase 4 Trial Results for i - GuruFocus
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal - Zacks Investment Research
Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy - Benzinga
Glaukos Reports Positive Phase 4 Results for iDose TR - Orange County Business Journal
Glaukos' iDose TR meets primary goal in phase 4 trial - Seeking Alpha
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal - Zacks Investment Research
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal - Yahoo Finance
Why is Glaukos stock climbing today? - Investing.com
Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery - BioSpace
Glaukos licenses rights to Revopsis’ RO-104 for retinal diseases - BioWorld News
Glaukos licenses preclinical tri-specific retinal biologic RO-104 from RevOpsis - AllSci
Glaukos Says Phase 4 Trial of iDose TR Meets Primary Efficacy Endpoint - marketscreener.com
Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery - Yahoo Finance
Glaukos Enters Exclusive License Agreement With RevOpsis Therapeutics for Biologic to Treat Retinal Diseases - VisionMonday.com
Glaukos Enters Exclusive License Agreement With RevOpsis Therapeutics for Biologic to Treat Retinal Diseases - VisionMonday.com
Glaukos Advances Eye Care Portfolio with Three-Year Epioxa Trial Data and Licensing Deal - Benzinga
Glaukos (GKOS) Shares Fall 13% Despite Positive Epioxa Trial Res - GuruFocus
Glaukos' Epioxa maintains corneal flattening and visual gains through 3 years in keratoconus - Ophthalmology Times
Will Three-Year Epioxa Data in Keratoconus Shift Glaukos' (GKOS) Corneal Portfolio Narrative? - Yahoo Finance
Glaukos slips as insider selling overshadows positive trial data for eye therapy - TradingView
Eli Lilly, Glaukos among market cap stock movers on Thursday - Investing.com
Glaukos Corp Azioni (GKOS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Glaukos Corp Azioni (GKOS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Navratil Tomas | Officer |
Oct 05 '26 |
Proposed Sale |
164.45 |
1,527 |
251,121 |
0 |
| Navratil Tomas | Officer |
Sep 25 '26 |
Proposed Sale |
154.28 |
1,615 |
249,158 |
0 |
| Navratil Tomas | CHIEF DEVELOPMENT OFFICER |
Sep 25 '26 |
Sale |
154.28 |
1,615 |
249,158 |
70,818 |
| Navratil Tomas | Officer |
Sep 16 '26 |
Proposed Sale |
166.92 |
1,457 |
243,207 |
0 |
| Navratil Tomas | CHIEF DEVELOPMENT OFFICER |
Sep 16 '26 |
Sale |
166.92 |
1,457 |
243,204 |
72,433 |
| Navratil Tomas | CHIEF DEVELOPMENT OFFICER |
Aug 28 '26 |
Sale |
180.67 |
13,744 |
2,483,104 |
73,890 |
| Navratil Tomas | Officer |
Aug 28 '26 |
Proposed Sale |
180.67 |
13,744 |
2,483,098 |
0 |
| Kliman Gilbert H | Director |
Aug 19 '26 |
Sale |
190.00 |
2,500 |
475,000 |
37,406 |
| Kliman Gilbert H | Director |
Aug 19 '26 |
Option Exercise |
25.77 |
2,500 |
64,425 |
39,906 |
| Kliman Gilbert H | Director |
Aug 19 '26 |
Proposed Sale |
190.00 |
2,500 |
475,000 |
0 |
4.38%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):